Over the years, ChEMBL has accepted 336 datasets deposited by the community. In fact, these data now comprise around 50% of the bioactivity data points. This is in addition to ChEMBL’s core data, bioactivity data extracted from the medicinal chemistry literature, and drug and clinical candidate data curated from regulatory authorities and clinical trials.
However, ChEMBL - like many other open access databases - is currently facing a reduction in funding. While we remain committed to maintaining the core of ChEMBL’s literature-extracted bioactivity data as well as drug data annotations, these constraints mean that in the future we may not be able to accept data depositions unless they are accompanied by appropriate funding. This applies particularly to those that require extensive curation or substantial manual intervention (*).
Any depositions that have been agreed or are already in progress will be handled as planned. Beyond this, we will continue to prioritise depositions that align closely with ChEMBL’s scope and community needs.
We understand that this may cause inconvenience, and we greatly appreciate your understanding as we navigate these changes. If you have questions about how this may affect your submissions, or would like to discuss funding mechanisms, please feel free to contact me at oboyle@ebi.ac.uk.
Footnote:
* This recent talk explains why curation is needed and what sort of curation activities are typically required.
Comments